The 2025 Most Favored Nation Executive Order has the potential to reshape the US drug pricing landscape by tying prices to the lowest paid in other developed nations. While this may lower costs for some patients, it could also disrupt global pricing strategies and ultimately reduce investment in innovation.

In this article, Lumanity’s experts break down the implications and share thoughts on how manufacturers can prepare to thrive in the new pricing ecosystem.

Fill out the form on the right to download the full article.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.